Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I actively personalized peptide vaccination with immunomodulators in newly diagnosed glioblastoma
NL-OMON44016Phase 1Active, not recruiting
- Sponsor
- Immatics
- Start
- Jun 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APVAC, poly iclc, sargramostim and temozolomide in glioblastoma (GBM) and brain neoplasm, sponsored by Immatics. Primary endpoints: Safety and tolerability, Feasibility and 1 more. Started Jun 2015; status: active, not recruiting.
02
Drugs
APVACpoly iclcsargramostimtemozolomide
03
Conditions
glioblastoma (GBM)brain neoplasm
Beyond the preview
Go deeper on NL-OMON44016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44016.